Page 33 - Research Models News Today

Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) – Equities research analysts at KeyCorp lowered their Q1 2022 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research note issued to investors on Sunday, April 10th. KeyCorp analyst P. Knight now anticipates that the medical research company will post […]

Oregon Public Employees Retirement Fund lowered its position in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 8.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,124 shares of the medical research company’s stock after selling 1,050 shares during […]

Oak Ridge Investments LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 5.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,100 shares of the medical research company’s stock after selling 240 shares during the period. Oak Ridge Investments […]

– Expands Charles River Accelerator and Development Lab (CRADL™) Footprint Providing Clients with Full-Service, Turnkey Research Space –– Adds More Than 15 Vivarium Facilities Across Three Key U.S. Biohubs –– Continued Expansion Expected in 2022 –WILMINGTON, Mass.--(BUSINESS WIRE)--$CRL #acquisition--Charles River L...

Dupont Capital Management Corp reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 25.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,606 shares of the medical research company’s stock after selling 1,541 shares during the […]

Analysts expect that Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) will report earnings of $2.43 per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Charles River Laboratories International’s earnings. The lowest EPS estimate is $2.42 and the highest is $2.45. Charles River Laboratories International reported earnings of […]

First Merchants Corp trimmed its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 2.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 6,506 shares of the medical research company’s stock after selling 145 shares during the period. First Merchants Corp’s holdings in Charles River Laboratories International were worth $2,451,000 at […]

Washington, DC (PRWEB) March 26, 2022 -- Washington, DC – Kathleen Lynch, longtime member of the senior team at the Folger Shakespeare Library, is retiring in

PFG Advisors acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) during the fourth quarter, Holdings Channel reports. The fund acquired 3,210 shares of the medical research company’s stock, valued at approximately $1,209,000. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. […]

Icon Wealth Partners LLC boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Get Rating) by 9.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,504 shares of the medical research company’s stock after buying an additional […]